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Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL) is an inherited cerebrovascular disease whose key 
features are recurrent transient ischemic attacks (TIA), strokes, migraine with 
aura, vascular dementia, and diffuse white matter abnormalities detectable through 
neuroimaging. The disease results from mutations in the NOTCH3 gene, encoding 
a transmembrane receptor involved in cellular signaling and fate during embryonic 
development. Genetic testing is the gold standard for diagnosing this condition, but 
the syndrome can be suspected clinically based on family history and characteristic 
findings of white matter changes. Nevertheless, different individual symptom 
types, onset, and disease severity, even among individuals in the same family, 
have been increasingly recognized. The molecular mechanisms by which NOTCH3 
mutations lead to vascular degeneration remain unclear. Most CADASIL-associated 
mutations result in either a gain or loss of cysteine residue in one of the 34 EGF-like 
repeats in the extracellular domain of the Notch3 protein, thus sparing the number 
of cysteine residues. More than 200 different mutations in the NOTCH3 gene have 
been reported in CADASIL patients, of which 95% are missense point mutations. 
Although it has been suggested that some mutations may be associated with a 
milder or more severe phenotype, so far no clear genotype-phenotype correla-
tion has been found. To date, no disease-modifying treatment is available for this 
condition.
Keywords: arteriopathy, leukoencephalopathy, cerebrovascular disease,  
NOTCH3 gene, Notch3 protein
1. Introduction
CADASIL (MIM 125310) is the acronym for cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy, coined in 1993 to 
define a hereditary small vessel disease of the brain affecting middle-aged adults 
and leading to disability and dementia [1, 2]. The disease was first described in 
1955 by Van Bogaert as “Binswanger’s disease with a rapid course in two sisters” [3]. 
Before 1993, a number of families with an apparently hereditary vascular dementia 
accompanied by a Binswanger-like arteriopathy were described [3–5], but only in 
1991, Tournier-Lasserve et al. [6] described nine patients of a single family, with 
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recurrent cerebrovascular ischemic events and dementia, variably associated with 
migraine headaches and epilepsy, suggesting the term “autosomal dominant syn-
drome with stroke-like episodes and leukoencephalopathy.” In 1993, a linkage analy-
sis of two unrelated European families led to the mapping of the defective gene to 
chromosome 19q12, and the syndrome was renamed CADASIL [1]. Compared with 
other inherited brain disorders such as Huntington’s disease or inherited early-onset 
Alzheimer’s dementia, CADASIL is still relatively unknown in the medical commu-
nity. This is not so much due to the fact that it is a rare disease but more to the fact 
that there is only a short history of recognition of the disease [7].
2. Clinical picture
CADASIL is an inherited cerebrovascular disorder, whose main clinical features 
are migraine with aura, recurrent subcortical ischemic attacks, strokes, vascular 
dementia, cognitive impairment, psychiatric disturbances, and apathy [8–16]. Due 
to the rarity of the disease, CADASIL is often overlooked and misdiagnosed; nev-
ertheless, the combined symptomatic and asymptomatic prevalence of CADASIL is 
estimated at least 10.7 per 100,000 adults [11, 12, 17–20]. Migraine with aura is an 
early sign, with average onset in the third decade of life, and it is typically reported 
to occur in 20–40% of patients [9, 21]. Transient ischemic attacks (TIA) or lacunar 
ischemic strokes are the most common signs, occurring in up to 85% of individuals 
with a mean onset in the fifth or sixth decade; usually they take the form of clini-
cal lacunar syndromes [21, 22]. The second most frequent clinical manifestation 
is cognitive impairment, often leading to dementia, which occurs in a very high 
proportion of patients by the age of 50 years. Mood disturbances are reported in 
20% of CADASIL patients, presenting as severe depressive episodes [21]. Moreover, 
researchers recognize apathy, which is independent from depression, as a major 
clinical manifestation, affecting about 40% of patients [23]. Patients with CADASIL 
exhibit, even more rarely, other clinical manifestations such as seizures in 5–10% 
of cases [22]; intracerebral hemorrhages [24], mostly in hypertensive patients, 
in 16–25% of cases [25, 26]; and, in a few cases, territorial infarcts [27], deafness 
[6], and parkinsonism [28]. All symptomatic patients present typical magnetic 
resonance imaging (MRI) findings, including noticeable signal abnormalities with 
hyperintense lesions on the T2-weighted images in the subcortical white matter, 
basal ganglia, and thalamus (a crucial difference from multiple sclerosis, a frequent 
mimic of CADASIL) [1, 6, 29–33]. Anterior temporal lobe hyperintensities may be 
more specific than external capsule changes and appear in young presymptomatic 
subjects [34]. In the vast majority of patients, brain MRI abnormalities precede the 
onset of symptoms by 10–15 years; thus, brain MRI is crucial for the diagnosis of 
CADASIL. Although marked population differences in the clinical and radiological 
manifestation of CADASIL have been recognized, potentially due to differences in 
underlying genetic mutations [21, 35–37], in the proper clinical evaluation based on 
symptoms suggestive of CADASIL, confluent anterior temporal pole white matter 
changes show sensitivity and specificity of 89 and 86%, respectively, based on case 
series. From a pathological point of view, CADASIL patients have a systemic non-
amyloid, non-atherosclerotic angiopathy affecting the walls of small blood vessels 
[38, 39]. The accumulation of granular osmiophilic material (GOM) within the 
smooth muscle cell basement membrane and the surrounding extracellular matrix 
is pathognomonic [40–42]. Because the arteriopathy in CADASIL is systemic, GOM 
deposits, which contain Notch3 proteins, among other poorly defined components 
[40, 43, 44], can be detected in arteries of many different organs, including dermal 
arterioles. In fact, actually GOMs are detected in skin biopsies, but the reported 
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sensitivity is variable [45, 46]. CADASIL is inherited dominantly, with over 500 
families detected worldwide and de novo cases observed sporadically [47].
3. Genetics
NOTCH3 gene mutations are causative of the disease. This gene, consisting of 
33 exons spanning roughly 7 kb and located on chromosome 19p13 [48], encodes 
a single-pass transmembrane heterodimer receptor Notch3 of 2321 amino acids 
involved in cellular signaling and fate during embryonic development [49, 50]. 
Notch3 protein comprising an N-terminal extracellular domain (NECD) involved 
in ligand binding, a transmembrane domain (NTMD), and an intracellular domain 
(NICD), which contains seven ankyrin repeats is required for downstream signal 
transduction (Figure 1) [51, 52]. More specifically, the NECD is non-covalently 
associated with the membrane-tethered intracellular domain, and it is composed of 
34 epidermal growth factor (EGF)-like repeats, followed by 3 Notch/lin12 repeats 
[53]. Each EGF-like repeat encompasses six cysteine residues, forming three pairs 
of disulfide bonds [54, 55]. The receptor is synthesized as single precursor protein 
which is cleaved during transport to the cell surface (S1 cleavage), where it is 
expressed as heterodimer. Upon binding of its ligand (a protein of the delta/jagged 
family) [56] at EGF repeats 10–11, Notch3 receptor undergoes two other proteo-
lytic cleavages: at first, N3 is cleaved (S2 cleavage) in its extracellular domain by a 
TNF-α-converting enzyme (TACE), subsequently in its transmembrane domain 
(S3 cleavage) in a presenilin-dependent manner. These proteolytic events, mutually 
dependent, generate the NICD fragment, which released from the NTMD enters 
the nucleus for activating the transcription of its target genes [53, 57–59]. Although 
the mutations are highly stereotyped, atypical phenotypes have been recognized, 
and the disease is probably underdiagnosed in most of the stroke population. Most 
CADASIL-associated mutations result in a gain or loss of cysteine residue in one 
of the 34 EGF-like repeats in the extracellular domain of the Notch3 protein, thus 
sparing the number of cysteine residues within the domain [60–62]. The alteration 
of the 3-D structure of the Notch3 protein, which is due to an aberrant dimerization 
of Notch3 through an abnormal disulfide bridging with another Notch3 molecule 
or with another protein, may play a central role in the pathogenesis of CADASIL 
[63–65]. A founder effect has been documented for the Finnish population but 
Figure 1. 
Schematic structure of Notch3 protein: Notch3 domains are differently colored.
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not for other countries [66]. To date, more than 200 different mutations in the 
NOTCH3 gene have been reported in CADASIL patients, of which 95% are hetero-
zygous missense point mutations [67]. The remaining consist of small deletions, 
duplications, in frame [68–71] and frame shift mutations, splice site mutations 
[36], and a small deletion not directly involving a cysteine residue [72]. Moreover, a 
three-nucleotide insertion has been described as the first pathogenic insertion [73]. 
Recent studies have found that mutations that do not affect the number of cysteines 
(unlike the typical mutations) seem to be associated with clinical CADASIL syn-
drome. However, the pathogenic role of these mutations is uncertain. Although it 
has been suggested that some mutations may be associated with a milder or more 
severe phenotype, so far no clear genotype-phenotype correlation has been found 
[7]. Moreover, only a few cases in the literature reported homozygous mutations of 
NOTCH3 [74–78]. Many polymorphisms have also been identified in the NOTCH3 
coding sequence [67], some of them leading to amino acid substitutions [79]. 
However, it is unknown whether these polymorphisms affect Notch signaling or 
whether they are involved in cerebrovascular disease.
4. Diagnosis
The pathology should be suspected in all cases with unexplained white matter 
hyperintensities and a family history of stroke and/or vascular dementia, consistent 
with an autosomal dominant inheritance. However, because affected family mem-
bers may have been misdiagnosed [80] and de novo cases have been described [69, 81], 
the lack of an apparent family history of CADASIL does not preclude the diagnosis. 
Several groups of clinicians [13, 14, 82] proposed suitable diagnostic strategies to be 
used in the clinical setting for the selection of patients to be subjected to NOTCH3 
gene analysis. In fact, in order to establish a correct diagnosis, clinical signs, neuro-
imaging findings, and family history need to be evaluated. Molecular screening is 
the gold standard for the diagnosis and is based on the identification in a proband 
of a pathogenic variation in the NOTCH3 coding sequence [36, 83]. With a sug-
gestive diagnosis of CADASIL, a single-gene testing or a multigene panel could be 
applied; if NOTCH3 screening is unavailable or gives a negative result in a patient 
with convincing clinical and MRI findings highly suggestive of CADASIL, a skin 
biopsy analysis using both Notch3 immunostaining and electron microscopy should 
be recommended to confirm or reject the diagnosis [21, 84]. If CADASIL phenotype 
overlaps with other inherited cerebrovascular diseases, a comprehensive genomic 
testing, such as exome sequencing, should be recommended in evaluating different 
genes involved.
5. Therapeutic approach and outlooks
CADASIL is one of the most monogenic causes of stroke. No disease-modify-
ing treatment is available. Being a genetic disease, two possible gene therapeutic 
approaches have been highlighted [85, 86], but, to date, only a symptomatic 
therapy focused on mitigating symptoms and management of the patient’s 
vascular risk factor can be applied [87, 88], beginning as immediate action to 
promote healthy individual behaviors, i.e., to refrain from smoking. Anyway, it is 
important that patients be referred to multidisciplinary and specialized centers, 
not only providing genetic counseling but also integrating the clinical and neuro-
imaging follow-up with neuropsychiatric, psychologic, and physical rehabilitation 
consultations.
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